Pfizer's Oral Small Molecule New Coronavirus Treatment Drug Paxlovid Approved in China

On February 12, in accordance with the relevant provisions of the "Drug Administration Law" and in accordance with the special approval procedures for drugs, emergency review and approval was carried out.
Announcement on the Import Registration of Wei Tablet Combination Packaging (ie Paxlovid)
.
The notice shows that the drug is an oral small molecule new coronavirus treatment drug for the treatment of adults with mild to moderate new coronavirus pneumonia (COVID-19) patients with high risk factors for progression to severe disease, such as advanced age, chronic kidney disease , diabetes, cardiovascular disease, chronic lung disease and other severe high-risk factors
.
Patients should strictly follow the instructions for medication under the guidance of physicians, and should pay close attention to the interaction information with other drugs listed in the instructions during use
.
The State Food and Drug Administration requires the marketing authorization holder to continue to carry out relevant research work, complete the conditional requirements within a time limit, and submit the follow-up research results in a timely manner
.
Source: State Food and Drug Administration